Granata Bio Acquires Oviva Therapeutics, Inc. to Advance Women's Health Solutions

Granata Bio has completed the acquisition of Oviva Therapeutics, Inc., a leading women's health biotech company focusing on treatments for female physiology and ovarian aging. Oviva's primary candidate, OVI-586, aims to extend women's health span by preserving ovarian function, offering potential applications in menopause, contraception, and in vitro fertilization.

The acquisition aligns with Granata Bio's mission to develop innovative fertility solutions, with OVI-586 providing a biologically grounded approach to improving ovarian response. This move signifies a significant milestone in advancing new therapies for fertility patients and addressing unmet needs in women's health.

Granata Bio is dedicated to collaborating on various drug classes to tackle reproductive medicine challenges. Oviva Therapeutics, Inc. is committed to improving women's aging experience through biomedical research and development, focusing on enhancing ovarian function to extend female healthspan. Granata Bio, on the other hand, is a U.S.-based biopharmaceutical company dedicated to innovating in women's health and infertility since 2018, with a pipeline comprising diverse fertility therapies.

Read more about the acquisition here.